Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

At Evonik, we are a global innovation hub for next-generation biomaterials working with our customers to take their ideas from concept to market. We offer global medical technology companies the industry's most comprehensive portfolio of tailored materials and services for the manufacture of medical devices that open up new possibilities for patient-specific treatment. 

As passionate experts with decades of experience in polymer chemistry and biotechnology, we combine a unique set of competencies in materials science, manufacturing technologies and regulatory expertise to enable our customers to develop next-generation medical devices. Thanks to our innovative strength and strong network of partners, we are always one step ahead, shaping the market by designing best-in-class biomaterials.

Rooted in science, driven by continuous innovation, and relentlessly committed to the United Nations Sustainable Development Goals, we empower our customers to accelerate time-to-market for new medical technologies that create life beyond limits.